The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Observational study of first-line therapy, including cetuximab in cases of nonresectable colorectal cancer: CORAL (interim report).
 
Hiroki Hashida
No Relationships to Disclose
 
Kei Muro
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono
 
Michio Itabashi
Honoraria - Bristol-Myers Squibb; Merck Serono
 
Yasuo Ohashi
Leadership - Statcom
Honoraria - Chugai Pharma; DNP Media Create; Shionogi
Research Funding - Astellas Pharma (Inst); Kowa (Inst); Kyowa Hakko Kirin (Inst); Takeda (Inst)
 
Kenichi Sugihara
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Merck Serono; Taiho Pharmaceutical
Research Funding - Bayer; Bristol-Myers Squibb; Chugai Pharma; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical